Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jan 20;62(8):1036–1042. doi: 10.1093/cid/ciw028

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 2. — Average atovaquone plasma concentrations (C_avg) in human immunodeficiency virus-infected patients receiving no antiretroviral therapy (no ARVs), atazanavir/ritonavir (ATV/r), or efavirenz (EFV) in combination with atovaquone 750 mg twice daily for 14 days (A) or 1500 mg twice daily for 14 days (B). Horizontal lines: solid line represents the C_avg previously associated with successful treatment of Pneumocystis jiroveci pneumonia (15 µg/mL); the dashed line represents the C_avg previously associated with successful treatment of toxoplasma encephalitis (18.5 µg/mL).